Evidence map›Paper›PMID 37763926›Full record

ArticleMicromachines2023

Rapid Production of Nanoscale Liposomes Using a 3D-Printed Reactor-In-A-Centrifuge: Formulation, Characterisation, and Super-Resolution Imaging.

Yongqing He, Davide De Grandi, Stanley Chandradoss, Gareth LuTheryn, Gianluca Cidonio, Ricardo Nunes Bastos, Valerio Pereno, Dario Carugo

Open access · goldAbstract read
In one paragraph

Article in Micromachines, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.2field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 12 citations in OpenAlex.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 5 institutions in 2 countries.

Yongqing HeDepartment of Pharmaceutics, School of Pharmacy, University College London, London WC1N 1AX, UK.
Davide De GrandiInstitute of Biomedical Engineering (IBME), Department of Engineering Science, University of Oxford, Parks Road, Oxford OX1 3PJ, UK.ORCID 0000-0001-8262-2978
Stanley ChandradossOxford Nanoimaging Limited (ONI), Oxford OX2 8TA, UK.
Gareth LuTherynNuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences (NDORMS), The Botnar Research Centre, University of Oxford, Windmill Road, Oxford OX3 7HE, UK.ORCID 0000-0002-5383-1081
Gianluca Cidonio3D Microfluidic Biofabrication Laboratory, Center for Life Nano- & Neuro-Science-CLN2S, Italian Institute of Technology (IIT), 00161 Rome, Italy.ORCID 0000-0002-9445-6994
Ricardo Nunes BastosOxford Nanoimaging Limited (ONI), Oxford OX2 8TA, UK.
Valerio PerenoOxford Nanoimaging Limited (ONI), Oxford OX2 8TA, UK.
Dario CarugoDepartment of Pharmaceutics, School of Pharmacy, University College London, London WC1N 1AX, UK.ORCID 0000-0002-1148-179X
Oxford Nanoimaging (United Kingdom) · GBNuffield Orthopaedic Centre · GBItalian Institute of Technology · ITUniversity College London · GBUniversity of Oxford · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Nanoscale liposomes have been extensively researched and employed clinically for the delivery of biologically active compounds, including chemotherapy drugs and vaccines, offering improved pharmacokinetic behaviour and therapeutic outcomes. Traditional laboratory-scale production methods often suffer from limited control over liposome properties (e.g., size and lamellarity) and rely on laborious multistep procedures, which may limit pre-clinical research developments and innovation in this area. The widespread adoption of alternative, more controllable microfluidic-based methods is often hindered by complexities and costs associated with device manufacturing and operation, as well as the short device lifetime and the relatively low liposome production rates in some cases. In this study, we demonstrated the production of liposomes comprising therapeutically relevant lipid formulations, using a cost-effective 3D-printed reactor-in-a-centrifuge (RIAC) device. By adjusting formulation- and production-related parameters, including the concentration of polyethylene glycol (PEG), temperature, centrifugation time and speed, and lipid concentration, the mean size of the produced liposomes could be tuned in the range of 140 to 200 nm. By combining selected experimental parameters, the method was capable of producing liposomes with a therapeutically relevant mean size of ~174 nm with narrow size distribution (polydispersity index, PDI ~0.1) at a production rate of >8 mg/min. The flow-through method proposed in this study has potential to become an effective and versatile laboratory-scale approach to simplify the synthesis of therapeutic liposomal formulations.

Indexed as

centrifugal flowliposomemicrofluidicssolvent exchangesuper-resolution microscopy

Identifiers

PMID37763926
PMCPMC10535575
OpenAlexW4387114624

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.